Skip to content

Multiple Sclerosis in the Elderly: Epidemiology, Clinical and MRI Characteristics

Multiple Sclerosis in the Elderly: Epidemiology, Clinical and MRI Characteristics

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03854123
Acronym
OLDMUS
Enrollment
159
Registered
2019-02-26
Start date
2018-09-21
Completion date
2020-09-23
Last updated
2022-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Geriatric population, EDMUS, OFSEP

Brief summary

Little is known about old MS patients. In a previous work, systematic search in Bordeaux, Strasbourg and Dijon university hospital regional MS center databases European Database for Multiple Sclerosis (EDMUS) retrieved 2% of 75 years old or older Multiple Sclerosis (MS) patients in the 3 databases. Data analysis showed that MS may switch off in the very old patients with mild progression and very few relapses. The project is to continue this preliminary work and extend it with a systematic study of MS in the elderly. The scientific aims: To add new insights into long lasting MS natural history in the growing population of elderly patients with MS.

Detailed description

75 to 77 years old MS patients whose disease began at 65 years old or earlier will be retrieved from the Observatoire français de la sclérose en plaques (OFSEP) which includes more than 50 000 MS patients in France. Accuracy of these patients' data from 65 to 75 years old will be thereafter checked and completed in 3 French MS centers: Lyon, Rennes and Bordeaux, participating to this database directly from the patients' clinical files. From these 3 MS centers around 150 MS patients from 75 to 77 years old are expected to be analysed on site. The data wich will be retrieved for these patients are: irreversible disability status scale progression, relapses, Magnetic Resonance Imaging (MRI) data, CSF data, Lublin classification of type of MS, McDonald 2005 and 2010 criteria, date and age at beginning of progression, characteristics and modality of relapses and clinical impairment at the beginning of the disease, treatments used, treatment failures and side effects, co morbidity, Barthel index, EuroQol-5D (EQ-5D), cognitive impairment (SDMT test), social life data and socio economic data. To the investigator's knowledge this will be the first systematic description of very old MS patients with data on long term natural history of MS and characteristics in this population of elderly MS patients.

Interventions

None listed

Sponsors

Observatoire Français de la sclérose en plaques (OFSEP)
CollaboratorUNKNOWN
Novartis
CollaboratorINDUSTRY
University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
75 Years to 77 Years
Healthy volunteers
No

Inclusion criteria

* Patients with McDonald 2001, 2005 or 2010 criteria of multiple sclerosis 75 to 77 years old MS patients at the time of inclusion * Patients whose beginning of MS was before 65 years old or 65 years old * Patients who signed OFSEP 's consent

Exclusion criteria

* Patients whose clinical data cannot be entered or for whom too much clinical data are missing * Alive patients older than 77 years or younger than 75 years the day of the inclusion in the study * Patients died before 65 years old

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of MS evolution with disability progression (irreversible Disability Status Scale) in 75 to 77 years Old MS Patients from the age of 65 years-old to present timeAt inclusion (day 0)Time to reach the irreversible Kurtzke disability status scale (DSS) score 4, 6 and 7

Secondary

MeasureTime frameDescription
Description of the clinical characteristics at 75 years OldAt inclusion (day 0)Clinical conversion to secondary progressive MS date
Description of the Cerebral MRI at 75 years OldAt inclusion (day 0)Number of lesions on T2 sequence if \<9, number of new T2 lesions, Number of Gadolinium enhancing lesions, T1-Hypointense Lesions (T1 Black Holes), MRI Barkhof Criteria and number of periventricular lesions if \<3,
Description of the paraclinical characteristics at 75 years OldAt inclusion (day 0)Distance walked (with or without help)
Frequency of clinical relapses in 75 years Old or Older MS Patients from the age of 65 years-old to present timeAt inclusion (day 0)
Description of the treatments at 75 years OldAt inclusion (day 0)Treatments of multiple sclerosis
Measure of health-related quality of life at 75 years OldAt inclusion (day 0)EQ-5D Instruments
Evaluation of cognitive functions at 75 years OldAt inclusion (day 0)Symbol digit modalities test (SDMT) test
Socio-demographic dataAt inclusion (day 0)sex

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026